is the fda stopping tirzepatide Compounders protest as removes off shortage list The Impact of New FDA

GLP-1s are usually shots that a person injects into their skin once or a few times a week

SURMOUNT clinical trials tracked tirzepatide use for up to 2 years with no new safety concerns emerging in the extended phase

Weight was measured at week 24 and again at week 48

By following these guidelines, you help maintain the integrity of semaglutide, ensuring it remains safe and effective for managing weight and blood sugar levels

Safety concerns : Important risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease, dehydration leading to acute kidney injury, hypoglycaemia (when used with insulin or sulfonylureas), and potential worsening of diabetic retinopathy with rapid glycaemic improvement

Even a reddish-brown colour of urine is considered abnormal